Role of TRIM72 ADP-ribosylation cycle in myocardial injury and membrane repair

Authors

• H Ishiwata-Endo
• J Kato
• A Tonouchi
• YW Chung
• J Sun
• LA Stevens
• J Zhu
• AM Aponte
• DA Springer
• H San
• K Takeda
• ZX Yu
• V Hoffmann
• E Murphy
• J Moss

Abstract

Specific mono-ADP-ribosylation of a protein arginine catalyzed by ADP-ribosyltransferase 1 (ART1), i.e., transfer of ADP-ribose from NAD to acceptor arginine, is reversed by ADP-ribosylarginine hydrolase 1 (ARH1) cleavage of the ADP-ribose-arginine bond. ARH1-deficient mice developed gender-specific cardiomyopathy, with myocardial fibrosis, impaired myocardial function, and ischemia-reperfusion injury. Membrane-repair protein TRIM72 was identified as substrate for ART1 and ARH1; ADP-ribosylated TRIM72 levels were greater in ARH1-deficient mice following ischemia-reperfusion injury. In C2C12 myocytes, ARH1 knockdown increased ADP-ribosylation of TRIM72, and delayed wound healing. Mutant TRIM72(R207K, R260K) that is not ADP-ribosylated, interfered with assembly of TRIM72 repair complexes at site of laser-induced injury. We hypothesized that regulatory enzymes ART1 and ARH1 and substrate TRIM72 would be in complexes and, were co-immunoprecipitated from mouse heart lysates. We propose a mono-ADP-ribosylation cycle involving recruitment of TRIM72 and other required molecules to sites of membrane damage is critical for wound repair and healing following myocardial injury.

Scientific Focus Area: Cell Biology

This page was last updated on Friday, March 26, 2021